{
  "id": "64163660690f196b5100001d",
  "type": "yesno",
  "question": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?",
  "ideal_answer": "Both daily prednisone and daily deflazacort were more effective",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33104035",
    "http://www.ncbi.nlm.nih.gov/pubmed/35723111",
    "http://www.ncbi.nlm.nih.gov/pubmed/35381069",
    "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
    "http://www.ncbi.nlm.nih.gov/pubmed/1822804"
  ],
  "snippets": [
    {
      "text": "Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\u2009<\u2009.001 for daily prednisone vs intermittent prednisone using a global test; P\u2009=\u2009.017 for daily deflazacort vs intermittent prednisone using a global test)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among patients with Duchenne muscular dystrophy, treatment with daily prednisone or daily deflazacort, compared with intermittent prednisone alternating 10 days on and 10 days off, resulted in significant improvement over 3 years in a composite outcome comprising measures of motor function, pulmonary function, and satisfaction with treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35723111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evidence from randomized clinical trials, prospective studies, meta-analyses, and post-hoc analyses suggests that patients receiving deflazacort experience similar or slower rates of functional decline compared with those receiving prednisone/prednisolone. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35723111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\u2009<\u2009.001 for daily predn",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}